James Hilger Insider Sell Transaction

Mr. James Hilger, the present Interim CFO & CAO at DaVita HealthCare Partners Inc (NYSE:DVA) 83.50 -0.19 -0.23% has lately been involved with a trade of 3,983 shares of the public firm, valued at $82.1 per share. The amount of the transaction was of $327,014 U.S. Dollars. In the last 30 days, he also unloaded 8,267 shares worth about $677,894 USD. This trade was reported on May 19, 2015 and is already filed with the Security Exchange Commission. The legal Form 4 is accessible to the public here. he today possess 0.01% of the total market cap of Davita Healthcare Partners Inc.

Davita Healthcare Partners Inc Stock Rating, Sentiment and Fundamentals

And his view is not unjustified – fifteen Wall Street stock analysts covering Davita Healthcare Partners Inc believe that the earnings for each share will be $3.77 in 2015, giving it a Price to Earnings ratio of 22.07 and a growth rate year on year not better than 12.50%.

* Read How Our Stock Ratings System Works

According to our research and trend-following model, we rate the Colorado-based company as Neutral. See the chart below. Davita Healthcare Partners Inc has had its stock price going up by 16.56% in the last 200 days alone, and its continuing to be on a weak uptrend.

Price Chart of Davita Healthcare Partners NYSE:DVA Stock

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Hedge Funds Ownership

Review of 13F SEC filings reveal that 468 hedge funds have shares of Davita Healthcare Partners Inc. In Q4 2014, the firm had 197.62% institutional ownership. That is a very high interest. They increased by 248.54 million the total shares they hold. As of that quarter these institutional players and asset managers owned 424.89 million shares. There were 30 funds that closed their positions and 158 that reduced them. A total of 50 funds opened new positions in Davita Healthcare Partners Inc and 189 increased their holdings.

16 hedge funds have this stock in their Top 10. These are: Foundation Asset Management Lp, Swift Run Capital Management Llc, Summit Partners L P, Timessquare Capital Management Llc, Cognios Capital Llc, Triple Frond Partners Llc, Hikari Power Ltd, Gates Capital Management Inc., Hikari Tsushin Inc., Roundview Capital Llc.

Bluestein R H & Co had the greatest investment with ownership of 10,650 shares as of Q4 2014 for 0.05% of the fund’s portfolio. Dock Street Asset Management Inc is another positive institutional investor having 57,383 shares of the company or 2.29% of their stocks portfolio. The stock is also 1.06% of the fund’s AUM. In addition The California-based fund First Republic Investment Management Inc. have 0.01% of their stock portfolio invested in the company’s market cap for 7,274 shares. The Massachusetts-based fund Foster Dykema Cabot & Co Inc Ma revealed it had purchased a stake worth 2.05% of the fund’s stock portfolio in Davita Healthcare Partners Inc. Geneva Advisors Llc is also confident in the public company, possessing 5,435 shares or 0.01% of their stock portfolio.

DaVita HealthCare Partners NYSE:DVA Company Profile

DaVita HealthCare Partners Inc. offers kidney care and manages and operates medical groups. DaVita HealthCare Partners Inc. operates through DaVita Kidney Care and HealthCare Partners (HCP). The Company’s services include outpatient hemodialysis services, hospital inpatient hemodialysis services, Home-based hemodialysis services, ESRD laboratory services and management services. It operates or provides administrative services through a network of outpatient dialysis centers in the United States that are designed for outpatient hemodialysis. The Company provides hospital inpatient hemodialysis services, excluding physician services, to patients in hospitals throughout the United States. DaVita Kidney Care is a provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. HCP manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, and Florida.

Davita Healthcare Partners Inc was formed in Delaware on 1994-04-04. At the moment its market worth is: $17.89 billion and it has 216.32 million shares outstanding. The company has 57900 employees. Today the company has 86.57% shareholders and the institutional ownership is 86.57%. The stock closed at $83.2 yesterday and it had average 2 days volume of 287000 shares. It is up from the 30 days average shares volume of 247747. Davita Healthcare Partners Inc has a 250 days low of $67.27 and a 52w high of $85.17. The stock price is above the 200 days SMA. Davita Healthcare Partners Inc last issued its quarterly earnings report on 05/04/2015. The company reported 0.86 EPS for the quarter, above the consensus estimate of 0.85 by 0.01. The company had a revenue of 3.29 billion for 3/31/2015 and 3.33 billion for 12/31/2014. Therefore, the revenue was -40,052,000 down.

James Hilger is also Chief Financial Officer of Pyramid Breweries Inc.

* Shares received upon the satisfaction of performance criteria underlying the award of performance share units.

* Represents the weighted average sale price of $82.1024. The range of prices for the sale of these shares was $82.02 – $82.21 – rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff – the Issuer – or a security holder of the Issuer – full information regarding the number of shares purchased or sold at each separate price.

* Includes 394 shares acquired under Issuer’s employee stock purchase plan on 12/31/2014.

Tagged: DaVita HealthCare Partners - (NYSE:DVA)James Hilger

...

Bay Area startup Outset Medical has built an at-home hemodialysis machine that’s meant to be simple for consumers with kidney failure to use – and has raised an impressive swath of capital to do so.

The Warburg Pincus-backed Outset just raised nearly $60 million dollars in an apparent Series B round, according to regulatory filings. However, a spokeswoman for the company said this isn’t the complete amount and will release a more accurate funding figure in the coming weeks. She didn’t comment further on the fundraise.

Why an at-home hemodialysis device? The standard process is quite cumbersome: Patients with kidney failure typically have to go to a clinic three times a week, and sit still for several hours while their blood is cleaned.

There’s been a movement to allow patients to undergo dialysis at home – but even then, the training time takes up to two months. It’s not exactly simple.

Outset’s blood-filtering device, called the Tablo, filters and purifies regular tap water, creates dialysate, takes a patient’s blood pressure and deliver medication.

It touts a simple user interface: With a touchscreen display, it offers step-by-step pictures and “conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis.” It’s in a compact, table-height device, Outset says – no hospital poles or additional equipment.

“We’ve set out to give people their time back,” Outset says of its device. “Tablo dramatically reduces the time involved in setting up and managing dialysis, whether at home in in clinic. There is simply less to do and less to learn.”

The device already has FDA clearance for use in clinics and hospitals, and is still working for approval in home use. It’s enrolling patients in clinical trials for at-home use this year.

This is a Warburg Pincus Ventures-backed company, launched in 2010, with two board of directors and CEO Leslie Trigg hailing from the private equity firm. Another listed investor is The Vertical Group, though this $60 million filing indicates 11 investors participated in the new round.

Warburg Pincus says Outset Medical’s competing in a $13 billion worldwide dialysis market. It writes about the Tablo:

With the dialysis patient population growing and dialysis reimbursement declining, Outset’s Tablo Hemodialysis System is aimed specifically at lowering costs for dialysis providers and meaningfully improving the care experience for patients.

The company’s clearly got aims to hit it big among consumers – check out the slick marketing in this video explaining the Tablo:

According to previous regulatory filings, it looks as though prior to this large fundraise, the company’s brought in about $9.5 million.

[PHOTO: Outset Medical]

...